Nucleic Acid Insights is bringing together a select Special Interest Group (SIG) of up to 50 leading experts from across the oligonucleotides community to address the sector’s most pressing challenges around improving the efficiency and sustainability of oligos manufacturing. This invitation-only initiative, taking place under the Chatham House Rule, provides a trusted, collaborative space for open discussion and actionable problem-solving - driving meaningful change through expert insight, strategic thinking and shared commitment. Sponsorship offers exclusive access to shape the discussion through thought leadership, gain targeted brand exposure to 15,000 Nucleic Acid Insights readers, and generate high value leads through resulting content outputs.

30 Dec

UPCOMING EVENT
WEBINAR
Charting a greener future for oligo manufacturing - Nucleic Acids Insights SIG 2026

Learn more

Join a hand-picked group of industry leaders at the inaugural Nucleic Acids Insights Special Interest Group.

The Nucleic Acid Insights Special Interest Group (SIG) brings together leading experts from across the oligonucleotides community to address one of the sector’s most urgent challenges: improving the sustainability and efficiency of oligo manufacturing. This invitation-only initiative provides a trusted, collaborative space for open discussion and actionable problem-solving - driving meaningful change through expert insight, strategic thinking, and shared commitment.

Nucleic Acid Insights SIG:

A community initiative designed to improve the efficiency and sustainability of oligos manufacturing

A 3-day virtual, invitation-only series of working groups engaging in candid discussion and strategic problem-solving around topics such as:

• Assessing pros and cons of emerging synthesis technologies – what will it take to drive their adoption and acceptance by regulators and industry?

• How to improve the yield, efficiency, and scalability of solid-phase synthesis?

• Driving innovation in downstream processing to enhance purification yield and efficiency

• What does the future hold for analytical tools innovation in oligonucleotide manufacturing?

• How should we adapt manufacturing tools and strategies to cater for novel, complex modalities?

• Defining the commercial oligonucleotide therapeutic manufacturing strategies of the future

A program of closed, confidential small-group discussion sessions, run under the Chatham House Rule to ensure frank, open debate. The source of both an independently peer reviewed and published White Paper and an official Meeting Report, each of which will be widely disseminated throughout the global sector

An important and timely positioning piece for Nucleic Acid Insights’ 15,000 registered users

An ongoing program of working group meetings and technical content, ensuring the recommendations are followed through and reinforced over the longer term:

• Webinars

• Progress reports

• Interview articles and Podcasts with SIG members

• Infographics

It's not a conference or virtual event. There will not be any delegates or exhibitors

The Topic

The topic we have chosen for the inaugural BioInsights Special Interest Group couldn’t be a more pressing one for the entire oligonucleotides community. The inefficiency and wastage long associated with oligo synthesis is both economically and environmentally unsustainable. This SIG is tasked with identifying optimal tools and strategies to Enhance Efficiency and Sustainability in Oligos Manufacturing and report back to the oligonucleotides sector with a roadmap to their successful implementation.

Topic streams and specific group discussion themes include:
• Assessing pros and cons of emerging synthesis technologies – what will it take to drive their adoption and acceptance by regulators and industry?
• How to improve the yield, efficiency, and scalability of solid-phase synthesis?
• Driving innovation in downstream processing to enhance purification yield and efficiency
• What does the future hold for analytical tools innovation in oligonucleotide manufacturing?
• How should we adapt manufacturing tools and strategies to cater for novel, complex modalities?
• How should the oligo therapeutics sector approach solvent recycling/reuse?
• Which oligo synthesis approaches will be best suited to different scales and applications in future?
• Defining the commercial oligonucleotide therapeutic manufacturing strategies of the future
• What is the current status in terms of the adoption and application of novel oligo manufacturing methods in the APAC region, India, and Oceania?